Jubbonti ® (denosumab-bbdz) and Wyost ® (denosumab-bbdz), interchangeable biosimilars to Prolia ® (denosumab) and Xgeva ® (denosumab), respectively, are now available from Sandoz. The ...

Investigators presented an interim analysis of the phase 3 ENLIGHTED trial of photodynamic therapy in patients with low-grade upper-tract urothelial cancer.

An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

Medical AI tools for clinicians and patients have advantages and disadvantages, including implicit bias in triage and virtual urgent care.

The immunotherapy CAN-2409 plus radiation therapy may fill an unmet treatment need for patients with localized intermediate- to high-risk prostate cancer.

Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...

Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

One-year incidence of psychosocial therapy initiation was 12.6 percent, while incidence of medication initiation was 2.8 percent ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

AMPLITUDE is the “first trial to show efficacy for the combination of inhibition of PARP and the androgen receptor pathway in metastatic, castration-sensitive prostate cancer with alteration of genes ...